alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-10.4




 Exhibit 10.4 

INVESTAR HOLDING CORPORATION 
 2014 LONG-TERM INCENTIVE
COMPENSATION PLAN 
 NOTICE OF EXCHANGE AND ASSUMPTION 

(Options) 
 Name of Option Holder: 

Number of Outstanding Options: 
 Pursuant to an Agreement and
Plan of Exchange between Investar Bank and Investar Holding Corporation (the “Company”), in November, 2013, Investar Bank became a wholly-owned subsidiary of the Company, and each outstanding share of common stock, $1.00 par value per
share, issued by Investar Bank (“Bank Stock”) was exchanged for one share of common stock, $1.00 par value per share, issued by the Company (“Company Stock”). 

Previously, you were granted options to acquire Bank Stock; the aggregate number of outstanding options you held immediately before the exchange is shown
above. In accordance with the Agreement and Plan of Exchange, your options to acquire Bank Stock have now been exchanged for rights to acquire a like number of shares of Company Stock (“Company Options”). Your Company Options have been
assumed and will now be administered under the Company’s 2014 Long-Term Incentive Compensation Plan, a copy of which is attached. In all other respects, the terms and conditions of your options, including the exercise price and the
circumstances under which your options may be forfeited or will expire, remain in force and effect. 
 You can request copies of your individual grants by
contacting Rachel Cherco at rachel.cherco@investarbank.com. You should retain a copy of this letter and the 2014 Long-Term Incentive Compensation Plan for your records. 

Attachment: 2014 Long-Term Incentive Compensation Plan
[Federal Register Volume 75, Number 166 (Friday, August 27, 2010)]
[Notices]
[Page 52771]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-21401]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-5415-N-08]


Notice of Availability: Notice of Funding Availability (NOFA) for 
Fiscal Year (FY) 2010 Indian Community Development Block Grant (ICDBG) 
Program for Indian Tribes and Alaska Native Villages

AGENCY: Office of the Chief of the Human Capital Officer, HUD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: HUD announces the availability on its Web site of the 
application information, submission deadlines, funding criteria, and 
other requirements for the FY2010 ICDBG NOFA. Approximately $65 million 
is made available through this NOFA, by the Consolidated Appropriations 
Act, 2010 (Pub. L. 111-117, approved December 16, 2009). Of this 
amount, up to $3.96 million is retained to fund Imminent Threat Grants. 
The purpose of the ICDBG program is the development of viable Indian 
and Alaska Native communities, including the creation of decent 
housing, suitable living environments, and economic opportunities 
primarily for persons with low and moderate incomes.
    The notice providing information regarding the application process, 
funding criteria and eligibility requirements can be found using the 
Department of Housing and Urban Development agency link on the 
Grants.gov/Find Web site at http://www.grants.gov/search/agency.do. A 
link to Grants.gov is also available on the HUD Web site at http://www.hud.gov/offices/adm/grants/fundsavail.cfm. The Catalogue of Federal 
Domestic Assistance (CFDA) number for the ICDBG is 14.862. Applications 
must be submitted electronically through Grants.gov.

FOR FURTHER INFORMATION CONTACT: For information concerning the ICDBG 
Program for Indian Tribes and Alaska Native Villages, contact Deborah 
M. Lalancette, Director, Office of Grants Management, Office of Native 
American Programs, Office of Public and Indian Housing, Office of 
Grants Management, Department of Housing and Urban Development, 1670 
Broadway, 23rd Floor, Denver, CO 80202; telephone number (303) 675-1600 
(this is not a toll-free number). Persons with speech or hearing 
impairments may access this telephone number via TTY by calling the 
toll-free Federal Information Relay Service during working hours at 
800-877-8339.

    Dated: August 24, 2010.
Barbara S. Dorf,
Director, Office of Departmental Grants Management and Oversight, 
Office of the Chief of the Human Capital Officer.
[FR Doc. 2010-21401 Filed 8-26-10; 8:45 am]
BILLING CODE 4210-67-P
| 1. | The Report fully complies with the requirements of      Section 13(a) or 15(d) of the Securities Exchange Act of 1934;      and |
|----|---------------------------------------------------------------------------------------------------------------------------------|

| 2. | To my knowledge, the information contained in the      Report fairly presents, in all material respects, the financial condition      and results of operations of the Company as of and for the period covered      by the report. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date: May 15, 2008 | By:    | /s/  Charles  Fust                                                                                            |
|--------------------|--------|-------------------------------------------------------------------------------------------------------------------------|
|               |   | Charles Fust                                                                                                            |
|               |   | Chief Executive Officer (Principal Executive Officer)Acting Chief Financial Officer(Principal Accounting Officer)  |
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000             DEC-31-2000
<PERIOD-START>                             JUL-01-2000             JAN-01-2000
<PERIOD-END>                               SEP-30-2000             SEP-30-2000
<CASH>                                       5,270,040                       0
<SECURITIES>                                         0                       0
<RECEIVABLES>                                        0                       0
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                             5,270,040                       0
<PP&E>                                     247,066,951                       0
<DEPRECIATION>                              24,689,787                       0
<TOTAL-ASSETS>                             227,647,204                       0
<CURRENT-LIABILITIES>                        5,270,040                       0
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                             0                       0
<OTHER-SE>                                 222,377,164                       0
<TOTAL-LIABILITY-AND-EQUITY>               227,647,204                       0
<SALES>                                     16,250,348              38,520,674
<TOTAL-REVENUES>                            16,288,746              38,604,499
<CGS>                                                0                       0
<TOTAL-COSTS>                                        0                       0
<OTHER-EXPENSES>                                92,306                 204,299
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                   0                       0
<INCOME-PRETAX>                             16,196,440              38,400,200
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                         16,196,440              38,400,200
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                16,196,440              38,400,200
<EPS-BASIC>                                      0.405                   0.960
<EPS-DILUTED>                                    0.405                   0.960


</TABLE>
f10q0314ex10vi_dandritbio.htm



Exhibit 10.6


 


LOAN AGREEMENT


 


Between 


 


Paseco ApS


c/o Crowe Horwath 


Strandvejen 58 5


2900 Hellerup


CVR-nr: 31 36 36 08


 


And


 


Dandrit Biotech A/S


Symbion Sciencepark Fruebjergvej 3 


21 00 København Ø


C VR-nr.  26027322


 


(Paseco ApS and Dandrit Biotech A/S are individually referred to as “Party” and jointly as the “Parties”)


 


Whereas:


 



	 	
A.

	
Dandrit Biotech A/S are  in the process of raising new equity via a reverse merger into an USA company and subsequent listing in the US







 



	 	
B.

	
Paseco ApS has agreed to issue certain loans to Dandrit Biotech A/S to ensure sufficient equity in Dandrit Biotech A/S during the process, and







 



	 	
C.

	
Dandrit Biotech A/S has  chosen to accept these loans







 


Now therefore, the parties have agreed as follows:


 



	
1.

	
The loans







 


Paseco ApS has agreed to issue the following loans to Dandrit Biotech A/S. 


 


DKK 2,500,000 issued as of February 15, 2014


DKK 2,300,000 issued as of March 18, 2014









  





  











  






 



	
2.

	
Interest







 


The loans will accrue interest at 5% per year as from the time where they are received by Dandrit Biotech A/S and until repayment is done.


 


If Dandrit Biotech A/S postpones repayment, cf. clause 3, the interest is increased to 7% from January 1, 2015 until repayment is done.


 



	
3.

	
Repayment







 


The loans are due on February 1, 2015 unless Dandrit Biotech A/S wish to postpone repayment until February 1, 2016.


 


If Dandrit Biotech A/S wish to postpone repayment as mentioned above they must inform Paseco ApS no later than December 31, 2014.


 


Dandrit Biotech A/S is entitled to repay the loans at any time.


 



	
4.

	
Other provisions







 


This Agreement supersedes all previous agreements, written or oral, between the Parties.


 


This Agreement is made in English and signed by the Parties in two copies, one copy for each Party.


 




	
DanDrit Biotech A/S

	  	  
	
Date: April 29, 2014

	  	
Date: April 29, 2014


	 	 	 
	
Signature /s/ Eric Leire                                            

	  	
Signature /s/ Niels Erik Nielsen                                    


	
Mr. Eric Jean Marie Leire, President

	  	
Mr. Niels Erik Nielsen


	
Chief Executive Officer

	  	
Chairman of the board of directors


	  	  	  
	
Paseco ApS

	  	  
	
Date: April 29, 2014


 

	  	  
	
Signature /s/ Ole Abildgaard                              

	  	  
	
Ole Abildgaard
```

[Congressional Bills 113th Congress]
[From the U.S. Government Publishing Office]
[S. 2218 Introduced in Senate (IS)]

113th CONGRESS
  2d Session
                                S. 2218

    To amend the Immigration and Nationality Act to provide for the 
  eligibility of certain territories and regions for designation for 
    participation in the visa waiver program and for other purposes.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             April 8, 2014

    Ms. Hirono (for herself, Mr. Lee, Mr. Kirk, and Ms. Klobuchar) 
introduced the following bill; which was read twice and referred to the 
                       Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
    To amend the Immigration and Nationality Act to provide for the 
  eligibility of certain territories and regions for designation for 
    participation in the visa waiver program and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Subnational Visa Waiver Program Act 
of 2014''.

SEC. 2. ELIGIBILITY OF CERTAIN TERRITORIES AND REGIONS FOR DESIGNATION 
              FOR PARTICIPATION IN VISA WAIVER PROGRAM.

    Section 217(c) of the Immigration and Nationality Act (8 U.S.C. 
1187(c)) is amended by adding at the end the following new paragraph:
            ``(12) Eligibility of certain territories and regions for 
        designation as program countries.--A territory or region of a 
        country--
                    ``(A) shall be eligible for designation as a 
                program country for purposes of this subsection if such 
                territory or region is accorded treatment under a 
                particular law of the United States, or any provision 
                thereof, different from that accorded to the country of 
                which it is a part; and
                    ``(B) may be designated as a program country for 
                purposes of this subsection if such territory or region 
                meets requirements applicable for such designation in 
                this subsection.''.
                                 <all>
```
#### PARKMONT PRODUCTS CORP. et al., Appellants, v. Scott WALKER et al., Appellees.

No. 5332.

Court of Civil Appeals of Texas, Waco.

May 23, 1974.

*76Wallace & Smith, Walter S. Smith, Jr., Waco, for appellants.

Moody & Crow, Frank M. Fitzpatrick, Waco, for appellees.

OPINION

McDONALD, Chief Justice.

This is an appeal by appellants Park-mont, et al., from order of the trial court quashing writs of execution on a judgment theretofore rendered.

Appellees have filed motion to dismiss, asserting all issues arising on this appeal are now moot.

The verified motion of appellees shows that subsequent to the order of the trial court quashing such writs of execution, appellants secured the issuance of ’ a second set of writs of execution, which were served on the identical properties subject to levy and seizure by the writs of execution quashed, and that such properties were sold at sheriff’s sale, and the proceeds credited on the final judgment.

An appellate court will not decide cases where no actual controversy exists between the parties at time of hearing. City of West University Place v. Martin, 132 Tex. 354, 123 S.W.2d 638. Moreover courts will not continue to litigate controversy that has ceased to exist, and appellate courts will not review judgment in cases where controversy between the parties has terminated, since such cases are moot. State v. Society for Friendless Children, 130 Tex. 533, 111 S.W.2d 1075; McNeill v. Hubert, 119 Tex. 18, 23 S.W.2d 331. The fact a question of costs is involved does not prevent a case from becoming moot, and an appellate court will not decide moot questions merely to determine the question of liability for costs. Lacoste v. Duffy, 49 Tex. 767; Robinson v. State, Tex.Cr.App., 29 S.W. 649; 3 Tex.Jur.2d, Sec. 50, p. 314.

To the same effect are: Grant v. Grant, Waco CCA, NWH, Tex.Civ.App., 358 S.W.2d 147; Blandin v. First-Wichita Nat. Bank, Ft. Worth CCA, NWH, Tex.Civ.App., 398 S.W.2d 663; Anderson v. Crain Chem. Co., Dallas CCA, NWH, Tex.Civ.App., 381 S.W.2d 364; Hand v. State, Houston CCA, NWH, Tex.Civ.App., 348 S.W.2d 72; Stephens v. Decker, Eastland CCA, NWH, Tex.Civ.App., 433 S.W.2d 28; 3 Tex.Jur.2d Sec. 50, pp. 313, 314.

In the case at bar all rights and issues involved in this appeal ceased to exist when the second sets of writs of execution were issued, the property seized and sold, and the proceeds credited on the judgment. The issues and points raised as to the validity of the trial court’s order quashing the original writs of execution are thus moot, and appellees’ motion to dismiss is sustained.

Since this case has become moot we express no opinion on any of the law questions involved, or upon the validity of the trial court’s order quashing the first set of writs of execution. State v. Society for Friendless Children, supra.

Appeal dismissed.
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA, 

Plaintiff-Appellee, 

 v. 

ANDREW THOMAS SWAGER, 

Defendant-Appellant.

No. 20-30212 

D.C. No. 6:09-cr-00012-CCL-1 

MEMORANDUM*

Appeal from the United States District Court

for the District of Montana

Charles C. Lovell, District Judge, Presiding

Submitted July 19, 2021**

Before: SCHROEDER, SILVERMAN, and MURGUIA, Circuit Judges. 

Andrew Thomas Swager appeals from the 13-month custodial sentence and 

lifetime term of supervised release imposed following the district court’s 

revocation of supervised release. Pursuant to Anders v. California, 386 U.S. 738 

(1967), Swager’s counsel has filed a brief stating that there are no grounds for 

* This disposition is not appropriate for publication and is not precedent 

except as provided by Ninth Circuit Rule 36-3.

** The panel unanimously concludes this case is suitable for decision 

without oral argument. See Fed. R. App. P. 34(a)(2).

FILED

JUL 21 2021

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2 20-30212 

relief, along with a motion to withdraw as counsel of record. We have provided

Swager the opportunity to file a pro se supplemental brief. No pro se supplemental 

brief or answering brief has been filed. 

Our independent review of the record pursuant to Penson v. Ohio, 488 U.S. 

75, 80 (1988), discloses no arguable grounds for relief on direct appeal. 

Counsel’s motion to withdraw is GRANTED.

AFFIRMED.
<PAGE>

                                                             Exhibit 16.1



                                                      ARTHUR ANDERSEN


                                                      Arthur Andersen LLP
                                                      Suite 5600
                                                      901 Main Street
                                                      Dallas, TX 75202-3799

                                                      Tel 214 741 8300

Office of the Chief Accountant
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549


April 26, 2000


Dear Sir/Madam:


We have read paragraphs (a) through (e) of Item 4 included in the Form 8-K dated
May 1, 2000 of Petro Stopping Centers, L.P. to be filed with the Securities and
Exchange Commission and are in agreement with the statements contained therein.


Very truly yours,


ARTHUR ANDERSEN LLP



By /s/ Arthur Andersen LLP
       Phillip R. Smith


VP


cc:  Mr. David A. Appleby, Vice President of Finance and Treasurer
     Petro Stopping Centers, L.P.
<PAGE>

                                                                    EXHIBIT 23.6

                        CONSENT OF INDEPENDENT ENGINEERS

The Board of Directors of Pure Resources, Inc.

     We hereby consent the incorporation by reference in the registration
statement on Form S-8 to be filed by Pure Resources, Inc. on or about the date
hereof, of references to our decommissioning estimates and references to our
firm included or incorporated in the proxy statement/prospectus of Pure
Resources, Inc. in its Registration Statement on Form S-4 (File No. 333-34970),
including under the heading "Experts" in the proxy statement/prospectus.

/s/ Robert C. Byrd
-----------------------------
Twachtman Snyder & Byrd, Inc.
Robert C. Byrd
Vice President

October 13, 2000
* Pursuant to Local Rule 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in Local Rule 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 96-10051 Conference Calendar

ALCARIO VERA, Plaintiff-Appellant,

versus BEVERLY COGBURN, Head Nurse; LISA JENNIFER BRIDE, Nurse; D. RAINS, LVN Nurse, Defendants-Appellees.

- - - - - - - - - - Appeal from the United States District Court for the Northern District of Texas

USDC No. 1:95-CV-20

- - - - - - - - - - June 26, 1996 Before HIGGINBOTHAM, BARKSDALE, and BENAVIDES, Circuit Judges.
PER CURIAM: * Alcario Vera, #657497, appeals from the district court’s dismissal pursuant to Fed. R. Civ. P. 12(b)(6) of his civil rights complaint brought under 42 U.S.C. § 1983. Vera contends that the magistrate judge erred by dismissing his complaint for failure to state a claim upon which relief may be granted, and in the alternative, based on the defendants’ assertion of qualifiedNo. 96-10051 - 2 - immunity. We have reviewed the record, the magistrate judge’s order of dismissal, and Vera’s arguments on appeal and find no reversible error. Accordingly, the judgment is AFFIRMED for essentially the same reasons stated by the magistrate judge. Vera v. Cogburn et al. , No. 1:95-CV-020 (N.D. Tex. Jan. 2, 1996). We caution Vera that any additional frivolous appeals filed by him or on his behalf will invite the imposition of sanctions. To avoid sanctions, Vera is further cautioned to review any pending appeals to ensure that they do not raise arguments that are frivolous.
AFFIRMED; SANCTIONS WARNING ISSUED.
May 23, 2014


 


Healthcare Corporation of America


66 Ford Road, Suite 230


Denville, NJ 07834


Attn: General Counsel


 


	 	Re:	Extension of certain Next Financing Round Covenants


 


Dear Sir:


 


Pursuant to a request from Healthcare Corporation
of America (“HCCA”), Selway Capital Holdings LLC has agreed to extend the time period referenced in the covenants set
forth in Section 6.2(a) and 6.2(b) of the Note Purchase Agreement (the “NPA”) dated April 3rd, 2014, until
May 30th, 2014.


 


This letter shall be deemed effective as
of the Closing of the NPA (as defined in the NPA). All other terms and conditions of the Bridge Loan Documents shall remain the
same and unaffected by this letter. This letter is not an indication of a waiver of any right or remedy available to Selway.







 


	 	Sincerely,
	 	 
	 	SELWAY CAPITAL HOLDINGS LLC
	 	 
	 	By: /s/ Andrew Intrater
	 	Name: Andrew Intrater
	 	Title: Board Member


 


Please indicate your agreement with the
foregoing by signing below and returning a copy of this letter to Selway Capital Holdings LLC.


 


 


ACCEPTED AND AGREED :


 


HEALTHCARE CORPORATION OF AMERICA 


 


By: /s/ Natasha Giordano


Name: Natasha Giordano


Title: Chief Executive Officer